December 25, 2012
Otsuka Pharmaceutical Co., Ltd.
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms approved for Carnitine Deficiency
- New Drug Levocarnitine approved in oral solution and injection forms, in addition to the L-Cartin® tablets; the only treatment in Japan for carnitine deficiency.
- Oral solution was developed to ease the patients having difficulties taking the carnitine tablets, and the injection form was developed for carnitine deficient patients who require immediate supplementation of carnitine, or for those unable to orally intake carnitine.
- Carnitine deficiency can be found in patients with inborn error of metabolism and in hemodialysis patients for example, through symptoms such as muscle pains, or even hypoglycemic coma in severe cases.
Tokyo, Japan, December 25, 2012 - Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) has received regulatory approvals today for L-Cartin FF oral solution and L-Cartin FF injection 1000mg, indicated for carnitine deficiency.
Information in this news release was current as of the original release date.